⌕
ImmunityBio · IBRX · Nasdaq
Tenet 51 · Mixed
Compare
$6.70+7.03%At closeTenet 51 · Mixed
$6.70+0.44 (+7.03%)
At close: Nov 18, 2026, 4:00 PM ET· Nasdaq · USD

ImmunityBio (IBRX) Institutional Ownership

13F filers reported holding 15.6% of ImmunityBio (IBRX) shares as of Sep 30, 2026, across 325 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
15.6%
Sep 30, 2026
13F filers
325
quarter ended Sep 30, 2026
13F value
$1.6B
166.2M shares
Quarter's fund flow
Mild accumulation
47 new · 36 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (47 new · 112 increased · 77 reduced · 36 closed · 53 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 50 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 325 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 50 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Oct 5, 2026Simon Barry J.directorDisposed · Open-market sale25,000$10.75↗
Oct 2, 2026Cohen CheryldirectorAcquired · Option exercise55,979$2.98↗
Oct 2, 2026Cohen CheryldirectorDisposed · Open-market sale81,056$10.50↗
Oct 2, 2026Cohen CheryldirectorDisposed · Option exercise55,979Stock Option (right to buy)—↗
Jul 2, 2026Cohen CheryldirectorAcquired · Option exercise55,979$2.98↗
Jul 2, 2026Cohen CheryldirectorDisposed · Open-market sale131,210$9.50↗
Jul 2, 2026Cohen CheryldirectorDisposed · Option exercise55,979Stock Option (right to buy)—↗
Jul 1, 2026Selecky ChristobeldirectorAcquired · Option exercise35,064$2.98↗
Jul 1, 2026Selecky ChristobeldirectorAcquired · Option exercise124,414$2.99↗
Jul 1, 2026Selecky ChristobeldirectorDisposed · Open-market sale159,478$9.02↗
Jul 1, 2026Selecky ChristobeldirectorDisposed · Option exercise35,064Stock Option (right to buy)—↗
Jul 1, 2026Selecky ChristobeldirectorDisposed · Option exercise124,414Stock Option (right to buy)—↗
Jun 30, 2026Selecky ChristobeldirectorAcquired · Option exercise700$2.98↗
Jun 30, 2026Selecky ChristobeldirectorAcquired · Option exercise300$2.99↗
Jun 30, 2026Selecky ChristobeldirectorDisposed · Open-market sale1,000$9.00↗
Jun 30, 2026Selecky ChristobeldirectorDisposed · Option exercise700Stock Option (right to buy)—↗
Jun 30, 2026Selecky ChristobeldirectorDisposed · Option exercise300Stock Option (right to buy)—↗
Jun 29, 2026Selecky ChristobeldirectorAcquired · Option exercise32,173$2.98↗
Jun 29, 2026Selecky ChristobeldirectorAcquired · Option exercise33,549$2.99↗
Jun 29, 2026Selecky ChristobeldirectorAcquired · Option exercise30,000$2.84↗

* Holdings as reported for Sep 30, 2026, 50 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of ImmunityBio do institutions hold?

13F filers reported holding 15.6% of ImmunityBio's shares as of Sep 30, 2026, across 325 filers.

How many 13F filers hold ImmunityBio?

ImmunityBio was held by 325 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.